Tissue | Expression Dynamics | Abbreviation |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003139619 | Prostate | Tumor | regulation of protein ubiquitination | 76/3246 | 210/18723 | 3.96e-11 | 2.68e-09 | 76 |
GO:001605514 | Prostate | Tumor | Wnt signaling pathway | 131/3246 | 444/18723 | 1.16e-10 | 7.11e-09 | 131 |
GO:019873814 | Prostate | Tumor | cell-cell signaling by wnt | 131/3246 | 446/18723 | 1.61e-10 | 9.69e-09 | 131 |
GO:000170115 | Prostate | Tumor | in utero embryonic development | 106/3246 | 367/18723 | 2.37e-08 | 8.09e-07 | 106 |
GO:190331219 | Prostate | Tumor | negative regulation of mRNA metabolic process | 38/3246 | 92/18723 | 5.44e-08 | 1.64e-06 | 38 |
GO:001657013 | Prostate | Tumor | histone modification | 126/3246 | 463/18723 | 5.51e-08 | 1.65e-06 | 126 |
GO:004563719 | Prostate | Tumor | regulation of myeloid cell differentiation | 67/3246 | 210/18723 | 1.71e-07 | 4.25e-06 | 67 |
GO:190370617 | Prostate | Tumor | regulation of hemopoiesis | 103/3246 | 367/18723 | 1.78e-07 | 4.38e-06 | 103 |
GO:005068613 | Prostate | Tumor | negative regulation of mRNA processing | 17/3246 | 29/18723 | 6.89e-07 | 1.40e-05 | 17 |
GO:190332214 | Prostate | Tumor | positive regulation of protein modification by small protein conjugation or removal | 47/3246 | 138/18723 | 1.50e-06 | 2.67e-05 | 47 |
GO:009872712 | Prostate | Tumor | maintenance of cell number | 45/3246 | 134/18723 | 3.80e-06 | 6.11e-05 | 45 |
GO:001982712 | Prostate | Tumor | stem cell population maintenance | 44/3246 | 131/18723 | 4.83e-06 | 7.52e-05 | 44 |
GO:001820512 | Prostate | Tumor | peptidyl-lysine modification | 99/3246 | 376/18723 | 6.77e-06 | 1.02e-04 | 99 |
GO:003139814 | Prostate | Tumor | positive regulation of protein ubiquitination | 40/3246 | 119/18723 | 1.25e-05 | 1.76e-04 | 40 |
GO:000749211 | Prostate | Tumor | endoderm development | 28/3246 | 77/18723 | 5.01e-05 | 5.55e-04 | 28 |
GO:003105612 | Prostate | Tumor | regulation of histone modification | 46/3246 | 152/18723 | 6.07e-05 | 6.59e-04 | 46 |
GO:000635412 | Prostate | Tumor | DNA-templated transcription, elongation | 31/3246 | 91/18723 | 8.58e-05 | 8.53e-04 | 31 |
GO:000647912 | Prostate | Tumor | protein methylation | 52/3246 | 181/18723 | 9.58e-05 | 9.35e-04 | 52 |
GO:000821312 | Prostate | Tumor | protein alkylation | 52/3246 | 181/18723 | 9.58e-05 | 9.35e-04 | 52 |
GO:000636812 | Prostate | Tumor | transcription elongation from RNA polymerase II promoter | 25/3246 | 69/18723 | 1.33e-04 | 1.23e-03 | 25 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CTR9 | SNV | Missense_Mutation | | c.2140C>G | p.His714Asp | p.H714D | Q6PD62 | protein_coding | deleterious(0.02) | benign(0.003) | TCGA-A8-A06O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD |
CTR9 | SNV | Missense_Mutation | | c.493N>A | p.Ala165Thr | p.A165T | Q6PD62 | protein_coding | deleterious(0.01) | probably_damaging(0.943) | TCGA-AR-A0TZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | Doxorubicin | PD |
CTR9 | SNV | Missense_Mutation | | c.2311N>A | p.Asp771Asn | p.D771N | Q6PD62 | protein_coding | tolerated(0.15) | benign(0.012) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
CTR9 | SNV | Missense_Mutation | rs777109871 | c.1555N>G | p.Leu519Val | p.L519V | Q6PD62 | protein_coding | deleterious(0.03) | benign(0.376) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CTR9 | SNV | Missense_Mutation | | c.2239N>A | p.Ala747Thr | p.A747T | Q6PD62 | protein_coding | deleterious(0.01) | benign(0.122) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
CTR9 | insertion | Frame_Shift_Ins | novel | c.783_784insACCTTTG | p.Tyr262ThrfsTer6 | p.Y262Tfs*6 | Q6PD62 | protein_coding | | | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
CTR9 | insertion | Nonsense_Mutation | novel | c.1373_1374insATAAAAGAGAT | p.Ala459Ter | p.A459* | Q6PD62 | protein_coding | | | TCGA-AR-A0U2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD |
CTR9 | SNV | Missense_Mutation | rs760130762 | c.1427N>T | p.Ala476Val | p.A476V | Q6PD62 | protein_coding | tolerated(0.28) | benign(0.083) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CTR9 | SNV | Missense_Mutation | | c.2732N>G | p.Ser911Cys | p.S911C | Q6PD62 | protein_coding | deleterious(0.03) | probably_damaging(0.971) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
CTR9 | SNV | Missense_Mutation | novel | c.2680G>A | p.Glu894Lys | p.E894K | Q6PD62 | protein_coding | tolerated(0.86) | benign(0.05) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |